As of June 21, 2025, Erytech Pharma SA (ERYP.PA) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Erytech Pharma SA's Forward P/E to Peers
To better understand Erytech Pharma SA's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Erytech Pharma SA (ERYP.PA) | - |
| Biofrontera AG (B8F.DE) | 72.66 |
| Innate Pharma SA (IPH.PA) | 18.65 |
| Novacyt SA (ALNOV.PA) | 2.02 |
| Kancera AB (KAN.ST) | 0.45 |
Compared to its competitors, Erytech Pharma SA's Forward P/E is difficult to compare due to insufficient data.